Mostrar el registro sencillo

dc.contributor.authorDierssen Sotos, Trinidad 
dc.contributor.authorGómez Acebo, Inés 
dc.contributor.authorde Pedro M
dc.contributor.authorPérez Gómez, B.
dc.contributor.authorServitja, S.
dc.contributor.authorMoreno, V.
dc.contributor.authorAmiano, P.
dc.contributor.authorFernández Villa, Tania
dc.contributor.authorBarricarte, Aurelio
dc.contributor.authorTardón García, Adonina
dc.contributor.authorDíaz Santos, M.
dc.contributor.authorPeiró Pérez, Rosana
dc.contributor.authorMarcos Grajera, Rafael
dc.contributor.authorLope, V.
dc.contributor.authorGracia Lavedan, E.
dc.contributor.authorAlonso, MH.
dc.contributor.authorMichelena Echeveste, MJ.
dc.contributor.authorGarcía Palomo, A.
dc.contributor.authorGuevara, M.
dc.contributor.authorCastaño Vinyals, G.
dc.contributor.authorAragonés, N.
dc.contributor.authorKogevina, M.
dc.contributor.authorPollán, Marina
dc.contributor.authorLlorca Díaz, Francisco Javier 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2016-10-05T12:33:24Z
dc.date.available2016-10-05T12:33:24Z
dc.date.issued2016
dc.identifier.issn1471-2407
dc.identifier.urihttp://hdl.handle.net/10902/9185
dc.description.abstractBackground: The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). Methods: In this case-control study, we report the NSAID – breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women’s characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics. Results: In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64–0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers. Conclusion: Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers. Keywords: Breast cancer, Non-steroidal anti-inflammatory drug, Hormone receptor positive breast cancer, HER2 positive breast cancer, Triple negative breast canceres_ES
dc.format.extent11 p.es_ES
dc.language.isoenges_ES
dc.publisherBioMed Centrales_ES
dc.rightsAtribución-NoComercial 3.0 Españaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.sourceBMC Cancer. 2016 Aug 20;16(1):660es_ES
dc.subject.otherBreast canceres_ES
dc.subject.otherHER2 positive breast canceres_ES
dc.subject.otherHormone receptor positive breast canceres_ES
dc.subject.otherNon-steroidal anti-inflammatory druges_ES
dc.subject.otherTriple negative breast canceres_ES
dc.titleUse of non-steroidal anti-inflammatory drugs and risk of breast cancer: The Spanish Multi-Case-control (MCC) studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1186/s12885-016-2692-4
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Atribución-NoComercial 3.0 EspañaExcepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial 3.0 España